Ni, Chen-Xu <br/><br/>
WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.  [electronic resource] 

 -  Oncotarget  Nov 2016 
 - 79544-79556 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.12822  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alkaloids--pharmacology<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Carcinoma, Hepatocellular--drug therapy<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cell Self Renewal--drug effects<br/>Dose-Response Relationship, Drug<br/>Doxorubicin--pharmacology<br/>Drug Resistance, Neoplasm--drug effects<br/>Epithelial Cell Adhesion Molecule--genetics<br/>Gene Expression Regulation, Neoplastic<br/>Glycogen Synthase Kinase 3 beta--metabolism<br/>Humans<br/>Inhibitory Concentration 50<br/>Liver Neoplasms--drug therapy<br/>Male<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Neoplastic Stem Cells--drug effects<br/>Phenotype<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Quinolizines--pharmacology<br/>Time Factors<br/>Tumor Burden--drug effects<br/>Wnt Signaling Pathway--drug effects<br/>Xenograft Model Antitumor Assays<br/>beta Catenin--metabolism